iSpecimen Inc. (NASDAQ:ISPC) Sees Significant Decline in Short Interest

iSpecimen Inc. (NASDAQ:ISPC) saw a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 79,700 shares, a decline of 33.1% from the February 28th total of 119,100 shares. Based on an average daily volume of 841,800 shares, the short-interest ratio is presently 0.1 days. Approximately 9.7% of the company’s shares are sold short.

Institutional Investors Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Bridgeway Capital Management LLC acquired a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned about 2.27% of iSpecimen at the end of the most recent reporting period. Institutional investors and hedge funds own 13.62% of the company’s stock.

iSpecimen Trading Down 7.8 %

iSpecimen stock traded down $0.09 on Monday, hitting $1.06. 34,820 shares of the stock traded hands, compared to its average volume of 410,458. The business’s fifty day simple moving average is $1.71 and its 200 day simple moving average is $3.19. The firm has a market cap of $1.02 million, a P/E ratio of -0.06 and a beta of 1.65. iSpecimen has a 1 year low of $1.04 and a 1 year high of $11.80.

About iSpecimen

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.